title: A world without Vioxx: to COX-2 or not to COX-2?
authors.affiliation: Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA. lsimon@bidmc.harvard.edu
authors.forename: Lee S
authors.initials: LS
authors.lastname: Simon
authors.forename: Vibeke
authors.initials: V
authors.lastname: Strand
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D010003:Osteoarthritis / Q000188:drug therapy*; D013450:Sulfones / Q000009:adverse effects*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib